Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B

Wei, Jia; Song, Liu-Wei; Fang, Yuqing; Wu, Xiaofeng; Liu, Danyang; Chun, Xu; Wang, Xiaomei; Wang, Wen; Lv, Dong-Xia; Li, Jun; Deng, Yongqiong; Wang, Yan; Huo, Na; Yu, Ming; Xi, Hongli; Liu, Dan; Zhou, Yixing; Wang, Guiqiang; Xia, Ningshao; Zhang, Mingxiang

doi:10.1097/md.0000000000000322

Cited by 60 publications

(57 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantitative detection of HBsAg (qHBsAg) and anti‐hepatitis B virus core antibody (anti‐HBc) was performed using available enzyme immunoassays (Roche Diagnostics, Penzberg, Germany) and sandwich enzyme‐linked immunosorbent assays, respectively . Serum HBV DNA was measured by COBAS AmpliPrep/COBAS TaqMan, with a minimum value of detection of 20 IU/mL . The levels of qHBsAg, anti‐HBc and HBV DNA were expressed as log 10 IU/mL.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

Zhao

Dong

Wang

2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Summary Liver biopsy is the reference method for antiviral therapy decision‐making in chronic hepatitis B (CHB) when alanine aminotransferase (ALT) is less than two times of upper limit of normal (<2ULN). Our aim was to explore noninvasive markers for antiviral therapy decision in CHB with ALT <2ULN. A total of 452 treatment‐naïve CHB patients with ALT < 2ULN who had undergone liver biopsy were analysed in this prospective multi‐centre study. If liver biopsy showed moderate or severe inflammation (histology activity index ≥ 5) or significant fibrosis (Ishak fibrosis score ≥ 3), antiviral treatment was recommended. We analysed data using univariate and multivariate analyses and receiver operating characteristic curves (ROC). Two hundred and sixty‐nine (59.5%) of 452 cases with ALT < 2ULN had moderate, severe or significant inflammation. Aspartate aminotransferase (AST) (P = 0.03), anti‐hepatitis B virus core antibody (anti‐HBc) (P = 0.003) and liver stiffness measurement (LSM) (P = 0.000) were independent variables for antiviral therapy decision‐making, with area under the ROC curve (AUROC) of 0.718, 0.703 and 0.819, respectively. Our novel AAF index, which combined AST, anti‐HBc and LSM, showed better performance with AUROC of 0.876, 0.877 and 0.876 in estimation, validation and total set. Finally, 247 (54.6%) of 452 patients could avoid liver biopsy based on AAF index. Furthermore, performances of 23 noninvasive models were unsatisfactory for antiviral therapy decision with AUROC < 0.800, which were inferior to AAF index. In conclusion, AST, anti‐HBc and LSM were related to antiviral therapy decision‐making among CHB patients with ALT < 2ULN. Thus, the novel AAF index was a more reliable noninvasive model for antiviral therapy decision‐making.

show abstract

Section: Methodsmentioning

confidence: 99%

“…11 Serum HBV DNA was measured by COBAS AmpliPrep/ COBAS TaqMan, with a minimum value of detection of 20 IU/mL. 10 The levels of qHBsAg, anti-HBc and HBV DNA were expressed as log 10 IU/mL.…”

Section: Hepatitis (Hepatitis C Virus Infection [Hcv] Hepatitis D Vimentioning

confidence: 99%

Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

Zhao

Dong

Wang

2018

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…These antibodies are known as the marker of a prior HBV infection or exposition, and they can persist 10-20 years or more after viral clearance. The level of these antibodies is known to fluctuate depending on the stage of HBV infection [27]. It has been shown that the levels were higher in cases of chronic HBV hepatitis than in OBI, and higher in OBI than in cases of past/cured HBV infection [28].…”

Section: Definitions Of Isolated Anti-hbc Pattern and Occult Hepatitimentioning

confidence: 99%

Isolated Anti-HBc: Significance and Management

Moretto

Catherine

Estève

et al. 2020

JCM

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is prevalent worldwide and is associated with dramatic levels of morbidity and mortality. Isolated anti-HBc (IAHBc) is a particular serological pattern that is commonly found in immunocompromised patients. There is ongoing debate regarding the management of patients with IAHBc. Herein, we summarize the current guidelines and the newest evidence. The frequency of IAHBc is variable, with a higher prevalence in some populations, such as persons living with HIV and others immunocompromised patients. The risk of HBV reactivation depends on host factors (including immunosuppression) and viral factors. It is now well established that immunocompromised patients can be classified into three groups for risk according to the type of immunosuppression and/or treatment. In patients at high risk, HBV therapy has to be considered systematically. In patients at moderate risk, the decision is based on the level of HBV DNA (preemptive treatment or monitoring and vaccination). In patients with low risk, HBV vaccination is another possible approach, although further studies are needed to assess the type of preemptive strategy.

show abstract

“…No cutoff value can confidently predict the disease activity due to significant overlap of HBsAg levels among patients with active and inactive diseases [14]. Furthermore, there is little information about hepatitis B core antibody (HBcAb) levels in the natural history of CHB [15,16]. And no data are available on hepatitis B e antigen (HBeAg) for differentiation of the natural phases of HBV infection.…”

Section: Introductionmentioning

confidence: 99%

Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection

et al. 2015

View full text Add to dashboard Cite

show abstract

Antibody to Hepatitis B Core Antigen Levels in the Natural History of Chronic Hepatitis B

Abstract: Supplemental Digital Content is available in the text

Cited by 60 publications

References 25 publications

Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal

Isolated Anti-HBc: Significance and Management

Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection

Contact Info

Product

Resources

About